The role of trefoil factor family in apparently healthy subjects administrated gastroprotective agents for the primary prevention of gastrointestinal injuries from low-dose acetylsalicylic acid: a preliminary study by Kawai, Takashi et al.
Original Article
 J. Clin. Biochem. Nutr. | September 2011 | vol. 49 | no. 2 | 136–140 doi: 10.3164/jcbn.11 10
©2011 JCBN
JCBN Journal of Clinical Biochemistry and Nutrition 0912-0009 1880-5086 the Society for Free Radical Research Japan Kyoto, Japan jcbn11-10 10.3164/jcbn.11-10 Original Article The role of trefoil factor family in apparently 
healthy subjects administrated gastroprotective 
agents for the primary prevention 
of gastrointestinal injuries from low dose 
acetylsalicylic acid: a preliminary study
Takashi Kawai,1,* Yu Takagi,2 Mari Fukuzawa,1 Tetsuya Yamagishi1 and Shinya Goto3
1Endoscopy Center, Tokyo Medical University Hospital, and 23rd Department of Surgery, Tokyo Medical University, 
6 7 1 Nishishinjuku, Shinjuku ku, Tokyo 160 0023, Japan
3Department of Medicine (Cardiology) and Metabolic Disease Center, Tokai University School of Medicine, Kanagawa 259 1193, Japan
*To whom correspondence should be addressed.    
E mail: t kawai@tokyo med.ac.jp
9 (Received 11 January, 2011; Accepted 9 February, 2011; Published online 25 August, 2011)
Copyright © 2011 JCBN 2011 This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unre- stricted use, distribution, and reproduction in any medium, pro- vided the original work is properly cited. It is well known that acetylsalicylic acid induces gastrointestinal
complication. Recently, trefoil factor family has been reported as
a mucosal protective factor. We focused on trefoil factor family as
one of defensive system for gastrointestinal injuries. The aim of
this trial was to evaluate trefoil factor family levels in the serum
of healthy subjects with low dose acetylsalicylic acid. Low dose
acetylsalicylic acid with placebo or proton pump inhibitor or
rebamipide were administered in 30 healthy subjects. Transnasal
endoscopy was performed at 0, 24 h, 3 and 7 day. Changing of
trefoil factor family (1,2,3) and numbers of gastric injuries were
evaluated. The numbers of gastric injuries were significantly
increased in the placebo group at 3 and 7 days. Injuries in the
proton pump inhibitor group were not induced, in the rebamipide
group were slightly induced. Trefoil factor family level in the
placebo group were decreased in 3 and 7 days compared with
prior to starting the trial. Trefoil factor family may have an impor 
tant association with acetylsalicylic acid induced gastrointestinal
damage. Proton pump inhibitor and rebamipide prevented low 
dose acetylsalicylic acid induced gastrointestinal complications
compared with the placebo group.
Key Words: Low dose ASA, transnasal endoscopy, rebamipide, 
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Introduction Atherosclerotic diseases including coronary heart disease and
cardiovascular events are associated with high frequencies of
morbidity and mortality in developed populations.(1) Administra-
tion of low-dose acetylsalicylic acid (ASA) has been recommended
for the primary and secondary prevention of these diseases.(2–3)
Indeed, observational registry demonstrated that approximately
70–80% of patients with a high risk of atherothrombosis were given
low-dose ASA for the prevention of future vascular events.(4)
On the other hand, it is well-known that low-dose ASA induces
gastrointestinal (GI) complications. In a multinational prospective
study of 187 patients receiving low-dose ASA for cardiovascular
disease prophylaxis, the prevalence of endoscopically-detected
peptic ulcers was 10.7% [95% confidence interval (CI); 6.3–15.1]
in the US 5). There was also a report on low-dose ASA-induced GI
complications for a Japanese population. Nema et al.(6) demon-
strated that mucosal injuries were found in 61.4% of low-dose
ASA users; the low-dose ASA users had more mucosal injuries
than the non-users (p<0.0001). The frequency of mucosal injuries
was not associated with the duration of ASA treatment. Also, there
were several reports on the preventive effect of anti-acid agents for
low-dose ASA-induced GI complications.
Proton pump inhibitor (PPI) was effective at reducing the risk of
endoscopic duodenal ulcer (RR = 0.44, 95% CI; 0.32–0.74) and
gastric ulcer (RR = 0.40, 95% CI; 0.32–0.51).(7) Shiotani et al.(8)
reported that taking PPI [adjusted odds ratio (OR): 0.09; 95%
CI: 0.02–0.39] was significantly associated with peptic ulcer.
Prostaglandin (PG) analogue and inducer include misoprostol and
rebamipide, and they are cytoprotective agents. Misoprostol is
well-known reducing serious GI complications in patients with
rheumatoid arthritis taking NSAIDs.(9) There is a randomized
controlled trial compared with misoprostol and rebamipide for
patients with NSAIDs-induced GI complications. It was resulted
that the incidence of peptic ulcer was 4.4% in the misoprostol
group and 4.5% in the rebamipide group.(10) Ono et al.(11) reported
that rebamipide prevent low-dose aspirin-induced gastric injury in
healthy subject.
In Europe it was reported that PPI was prescribed in 99.4%
cases for prevention of low-dose ASA-induced GI complica-
tions.(12) On the other hand, in Japan cytoprotective agents (ex.
rebamipide) were widely used for prophylaxis of gastrointestinal
complication induced by low-dose ASA. Actually PPI and
cytoprotective agents were prescribed equally for prophylaxis of
gastrointestinal complication induced by low-dose ASA.(13)
In our previous report, low-dose ASA-induced GI complica-
tions for healthy subjects were strongly induced at 3 days and
were reduced at 7 days.(14) This phenomenon was concluded as
adaptation. The mechanism of adaptation is not yet well under-
stood, therefore we conducted this study to clarify the phenomenon
by measuring trefoil factor family (TFF).
Recently, TFF has been reported to be a mucosal protective
factor. TFF is a mucin-associated protein involved in the mainte-
nance of mucosal barrier and restitution of lining epithelial cells.(15)
TFF were categorized into three family members, TFF1, 2, and 3.
TFF are a family of short peptides, rich in disulfide bonds that
form intramolecular loops.(16) TFF are up-regulated in the surface
epithelial cells at the margin of gastric ulcer.(17) We focused on
TFF as one candidate defensive system for ASA-induced GI
complications.
The aim of this trial was to evaluate the level of TFF in the
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serum for healthy subjects on low-dose ASA, ASA plus PPI, and
ASA plus rebamipide, and the preventive effect of PPI and
rebamipide.
Materials and Methods
A randomized, double-blind, placebo-controlled trial comparing
placebo, PPI and rebamipide were performed in 30 healthy subjects.
Ten were assigned as the PPI group, ten were as the placebo group,
and ten were as the rebamipide group. The study protocol was
approved by the Ethics Committees of Tokyo Medical University
Hospital, and written informed consent was obtained from all
subjects.
Inclusion and exclusion criteria. Inclusion criteria were i)
lack of gastric conditions such as bleeding or ulcer on endoscopy,
and ii) H. pylori negativity on 13C urea breath test. Subjects who
were taking other medication were excluded.
Study design. The study design was as shown in Fig. 1. The
thirty healthy subjects were divided into three groups: those taking
ASA 100 mg with placebo, omeprazole 20 mg, or rebamipide
300 mg. The groups with drug administration received their dose
three times daily for 7 consecutive days. Transnasal endoscopy
was performed at 0 and 24 h on the first day, and again on the third
and seventh days.
Randomization. Subjects were recruited for the treatment
sequences in a random fashion according to a randomization
schedule for the treatment period. A randomization number that
was associated with a specific treatment, either rebamipide,
omeprazole, or placebo, was assigned to each subject in the study.
Randomized numbers were generated by SAS program.
Endpoints. The primary endpoint was to evaluate short-term
changes of gastric mucosa in healthy subjects who took low-dose
ASA with placebo, omeprazole, and rebamipide. The secondary
endpoint was to evaluate short-term changes of TFF (TFF1, 2, and
3) levels in serum.
Evaluation criteria. The categories of injury were erythema,
erosions, petechia, and ulcers. Erythema was defined as a region
clearly redder than surrounding mucosa, erosion as a region with
mucosal deficit, petechia as a bleeding region without mucosal
deficit, and ulcer was defined as greater than 5 mm. Gastric
mucosal injuries detected on endoscopy were calculated among
numbers of erosions, erythema, petechia, and ulcers. All GI
injuries were counted in each time course.
The number of erythema, erosions, petechia and ulcers were
counted to evaluate low-dose ASA-induced GI injuries compared
among the placebo, omeprazole, and rebamipide group. The
number of erythema, erosions, petechia were evaluated as changing
their numbers compared with before starting study and after (after
had three points, 24 h, 3 days, and 7 days).
Endoscopic evaluation was done by two endoscopists blinded
for subject number and groups. If the result was different, re-
evaluation and discussion were done.
Measurement of serum and TFF1, 2, and 3 levels in the
serum. Serum samples were obtained for all subjects at 0, 24 h
on the first day, 3rd and 7th days after starting this trial. TFF1,
TFF2, and TFF3 levels in the gastric juice and serum were
measured by ELISA as described recently.(18,19) All measurements
were performed in duplicate within the same assay run.
Evaluation of adverse events. The following GI symptoms
and complications were to be recorded in the symptom diary for
all subjects throughout the study period.
Statistical analysis. Difference of time course in TFF levels
were shown as absolute different and 95% confidence index.
Findings of p<0.05 were considered significant. Statistical analyses
were performed using SAS® version 8.2 (SAS Institute, Cary,
NC). Details of the statistical analysis were analyzed by intention-
to-treat analysis.
Results
Thirty healthy subjects were enrolled. The mean age of the
subjects was 28 ± 4 years. Nineteen were male and eleven were
female. In addition, the backgrounds of all subjects who had
smoking, drinking, and histology data before starting trial were
shown in Table 1. No subjects had H. pylori infection. Thirty
healthy subjects were divided into three groups: low-dose ASA
plus placebo group, omeprazole, and rebamipide groups.
Short term change of gastric mucosa by administration
of low dose ASA among the control, placebo, omeprazole,
and rebamipide groups. Changing of erosion, erythema, and
petechiae among three groups from before starting the trial were
shown in Table 2. The number of erosion and erythema were in-
Fig. 1. Study design.
Table 1. Demographic in healthy subjects
Omeprazole Rebamipide Placebo
(n =1 0 ) ( n =1 0 ) ( n =1 0 )
Age (mean ± SD) 28 ± 42 8 ± 52 7 ± 3
Gender (male/female) 6 : 4 7 : 3 6 : 4
Smoking 2 : 10 3 : 10 2 : 10
Alcohol in take 9 : 10 9 : 10 9 : 10
Number of injury
erosion 4.4 ± 10.8 0.5 ± 1.2 0.9 ± 1.5
erythema 4.0 ± 6.4 9.1 ± 13.9 3.5 ± 3.8
petechiae 8.2 ± 22.4 2.7 ± 4.2 2.4 ± 3.3doi: 10.3164/jcbn.11 10
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creased in the placebo group at 3 days compared with before
starting the trial. Afterward these changes were recovered at 7
days. The number of petechiae was increased in the placebo group
at 7 days compared with before starting the trial. The number of
erythema was increased in the placebo group at 3 days compared
with the omeprazole and the rebamipide groups, 9.6 ± 10.5 vs
1.4 ± 6.8 (p = 0.0611) vs 0.3 ± 4.2 (p = 0.0327). The number of
petechiae was increased in the placebo group at 7 days compared
with the omeprazole and the rebamipide groups: 8.3 ± 8.8 vs −
5.6 ± 23.6 (p = 0.0213) vs −1.6 ± 5.2 (p = 0.0335), respectively.
Evaluation of TFF1, 2, and 3 levels in the serum. TFF 
levels at 3 day in the placebo group were decreased compared with
before taking ASA, and were recovered at 7 days. On the other
hand, TFF levels in PPI group were not changed compared with
before starting the trial and 3, 7 days. TFF1, 2 levels at 3 day in
rebamipide were significantly decreased compared with before
taking ASA, and were also recovered at 7 days. (shown in Table 3)
Adverse events. The number of gastrointestinal symptoms
or complications was recorded in the symptom diary by all
subjects throughout the study period. There were no serious
side-effects in three treatment groups.
Discussion
The action of ASA is derived from irreversible inhibition of
the cyclooxygenase-1 enzyme, resulting in the inhibition of
thromboxane A2 formation, however the novel effects of ASA
mediated by its salicylate moiety complement the role of the acetyl
moiety in terms of its platelet inhibitory effect. The action of ASA
resulted from an interaction among platelet activation, endothelial
inflammation/activation, and oxidative stress.(20) However, they
may have contrary effects for GI mucosa.
In this study, it is interesting to note that the peak of erythema
and erosion was induced on the 3rd day, and restored on the 7th
day in spite of continued administration of ASA (Table 2).
Konturek et al.(21) reported about adaptation of aspirin-induced
gastric damage. Gastric injury may repeatedly occur and heal as a
natural process, but it is not clear what kind of cycle is being
repeated. In this study, the healing effect of placebo at 7 days may
be resulted by adaptation, and also this action by adaptation may
have a close relation to TFF.
TFF is relatively new family peptides which bear the three-loop
trefoil domain. They are assumed to play important role in the
protection of gastrointestinal mucosa.(22,23) TFF1 is produced
mainly in the stomach, in superficial cells of the body and antral
mucosa.(22,24) TFF2 is abundant in the mucous neck cells in the
body and in the antral gland of the stomach.(22,25) TFF3 is
expressed in the goblet cells of lower intestine and its expression
in not found in normal gastric mucosa.(17) We also planned the
measurement of TFF in gastric mucosa, but this procedure requires
the use of biopsy forceps. We must take measurements many times
(pre, 24 h, 3, 7 day), so constant use of the forceps cause injury to
gastric mucosa. Such injuries could also conceivably be caused by
low-dose aspirin as well. We cannot tell if the injury is caused by
the forceps or low-dose aspirin. Therefore we used serum TFF in
this study.
mean ± SD.
24 h 3 days 7 days
Erosion
Placebo 0 ± 1.4 2.4 ± 3.1 1.4 ± 2.8
Omeprazole 2.9 ± 3.7 1.9 ± 4.5 –2.3 ± 8.5
Rebamipide –0.1 ± 1.5 0.9 ± 1.8 1.2 ± 3.4
Erythema
Placebo 1.8 ± 3.6 9.6 ± 10.5 2.2 ± 6.6
Omeprazole –0.1 ± 4.7 1.4 ± 6.8 –1.2 ± 6.3
Rebamipide –0.7 ± 3.6 0.3 ± 4.2 1.5 ± 5.8
Petechiae
Placebo 2.4 ± 4.3 1.4 ± 5.1 8.3 ± 8.8 
Omeprazole –2.1 ± 18.4 0 ± 11.2 –5.6 ± 23.6 
Rebamipide 0.1 ± 6.4 –0.4 ± 4.8 –1.6 ± 5.2
p =0 . 0 3 2 7
p =0 . 0 6 1 1
p = 0.0335
p =0 . 0 2 1 3
Table 2. Changing numbers of injuries from before treatment
Table 3. Circadian variation of TFF1, 2, and 3 serum levels
* compared with before TFF levels p<0.01.
pre 24 h 3 days 7 days
TFF1
Placebo 0.473 ± 0.225 0.449 ± 0.227 (−5.1) 0.379 ± 0.111 (−19.9) 0.482 ± 0.216 (1.9)
Omeprazole 0.432 ± 0.168 0.452 ± 0.170 (4.6) 0.421 ± 0.167 (−2.5) 0.495 ± 0.188 (14.6)
Rebamipide 0.560 ± 0.228 0.534 ± 0.189 (−4.6) 0.393 ± 0.090 (−29.8)* 0.489 ± 0.153 (−12.7)
TFF2
Placebo 4.100 ± 1.500 3.449 ± 0.620 (−15.9) 3.093 ± 0.521 (−24.6) 3.093 ± 0.521 (−11.3)
Omeprazole 3.193 ± 0.499 3.449 ± 1.132 (8.0) 3.330 ± 1.222 (4.3) 3.431 ± 1.027 (7.5)
Rebamipide 3.732 ± 1.016 3.525 ± 1.188 (−5.5) 3.294 ± 1.176 (−11.7)* 3.918 ± 1.220 (5.0)
TFF3
Placebo 3.140 ± 0.976 3.140 ± 0.976 (−12.6) 2.496 ± 0.943 (−20.5)* 3.000 ± 1.015 (−4.5)
Omeprazole 3.169 ± 1.228 3.140 ± 0.976 (−7.8) 3.279 ± 1.204 (3.5) 2.946 ± 1.337 (−7.0)
Rebamipide 2.509 ± 1.247 2.404 ± 1.207 (−4.2) 2.322 ± 1.144 (−7.5) 2.732 ± 1.225 (8.9) J. Clin. Biochem. Nutr. | September 2011 | vol. 49 | no. 2 | 139
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The relationship between TFF and NSAIDs is still somewhat
controversial. Koitabashi et al.(26) reported Indometacin up-regulates
TFF2 expression in gastric epithelial cell in vitro. Alderman et
al.(27) investigated relationship between TFF1 & TFF2 and adapta-
tion to aspirin in gastric mucosa in vivo. They reported that quan-
tification of TFF1 and TFF2 protein level in adapted group slightly
were decreased (but no significant change) than that of control
group. Moreover there are no report related serum TFF and mu-
cosal TFF, but transvenous administration of TFF inhibited eth-
anol induced injury.(28) It is possible that serum TFF is strongly
related with mucosal TFF. TFF may possibly play an important
role in gastric mucosal damage.
In addition, we investigated the relationship between TFF levels
and mucosal damage by low-dose ASA with PPI or rebamipide.
Low-dose ASA-induced GI injuries have been prevented in the
PPI group, the level of TFF in the PPI group were not significant
changed compared with before starting the trial. This was based on
the acid secretion inhibitory action of PPI. On the other hand,
rebamipide prevented GI injuries in spite of decrease in TFF
levels. These results may show that protective effect of rebamipide
was not influenced by TFF levels. Suzuki et al.(29) reported that
rebamipide significantly suppressed ASA-induced gastric damages
by protection of tight-junction. Iijima et al.(30) reported on the
output of total gastric mucin was significantly increased by
rebamipide. These actions may be one of rebamipide’s GI mucosal
protective mechanisms.
Although PPI is the most effective drug for patients with ASA-
induced GI complications, it also has limitations, such as poor
metabolizer as well as ASA and/or clopidogrel resistance. Some
patients are known to have PPI resistance.(31,32) PPI can be classified
as having either the phenotype of an extensive metabolizer or that
of a poor metabolizer based on the level of CYP2C19 activity.(33,34)
Manifestation of a PPI-independent preventive system for GI
complications would be useful because there are numerous
patients with PPI resistance. A candidate drug with a mechanism
different from that of PPI should be developed. More recent
interesting report demonstrated that concomitant use of PPI and
gastroprotective effects of rebamipide, suggesting that it may be a
good choice in aspirin users with gastroduodenal toxicity that is
not suppressed by acid suppressants alone.(35)
Total care between cardiovascular events and GI complications
are important for patients with atherosclerotic diseases who are
taking anti-platelet agents. Moreover, various patients often
have different circumstances; therefore it is necessary to prepare
various clinical options. Recently, ASA-related small intestinal
complication was well discussed. Niwa et al.(36) demonstrated
that rebamipide has the preventive effect for NSAID-induced
small-intestinal injuries. This result showed the possibility for
management of the entire gastrointestinal tract including the small
intestinal mucosa by concomitant therapy of PPI + rebamipide.(37)
In addition, most patients who take ASA are asymptomatic, even
if GI ulcer and bleeding occurs, and there is no option for these
patients, except endoscopy testing. However, periodic diagnosis
is essential. Recently, transnasal upper-gastrointestinal endoscopy
has become popular; we too used this modality in this trial, and
no subjects withdrew. Transnasal endoscopy has been developed
as an alternative to trans-oral endoscopy to reduce medical costs
as well as the risks associated with conscious sedation.(38,39) In
addition, transnasal upper GI endoscopy is a comfortable and
conventional test that imposes less stress due to sedation, such as
respiratory depression, hypotension, paradoxical agitation, and
anaphylaxis,(40) and most importantly, imposes less load on the
cardiovascular pulmonary system.(41) This modality will become
the mainstream method for periodical diagnosis. In this study,
not only PPI but also rebamipide showed a preventive effect for
low-dose ASA-induced GI complications. It was clear that the
action of PPI was by acid suppression without TFF. The role of
TFF was reported to be site protective action. TFF is part of the
gastric mucosal defensive system.
In conclusion, Administration of low-dose ASA decreased TFF
levels in serum. TFF may have an association with ASA-induced
GI damage. These relations between GI-mucosal damage and the
expression of various TFF, and the search for drugs that have an
action for TFF, deserve further investigation.
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